GHRH biology and the GHRH receptor
Growth-hormone-releasing hormone is a 44-amino-acid peptide released from parvocellular neurons in the hypothalamic arcuate nucleus. It reaches the anterior pituitary through the hypothalamo-hypophyseal portal circulation and stimulates GH release from somatotroph cells through the GHRH receptor — a class B G-protein-coupled receptor coupling primarily to Gαs and cAMP.
GHRH release is pulsatile, alternating with somatostatin release to produce the characteristic pulsatile pattern of circulating GH. Native GHRH has a very short circulating half-life — on the order of minutes — because it is rapidly cleaved at the Ala2 position by dipeptidyl peptidase-4 (DPP-4), the same protease responsible for inactivating GLP-1.
GHRH(1-29): the minimum active fragment
GHRH fragment-mapping studies through the 1980s established that the N-terminal 29 residues of native GHRH retain full agonist activity at the GHRH receptor. Truncation shorter than 29 residues progressively reduces potency; extension beyond 29 residues adds regulatory content without altering fundamental agonist behaviour.
Sermorelin is the synthetic 29-residue fragment with a C-terminal amide, matching the native cleavage-generated form. It is often referred to in the research literature simply as "GHRH(1-29)-NH₂" or "GHRH(1-29)".
Pharmacokinetics: short-acting by design
Sermorelin carries no substitutions to block DPP-4 cleavage and no fatty-acid or albumin-anchoring modifications to extend half-life. Its plasma half-life is measured in minutes — comparable to native GHRH — because the same clearance mechanisms operate on both.
In a research context, that short half-life is a feature rather than a limitation. Sermorelin provides a stimulus that closely resembles endogenous GHRH pulsatility: transient, quickly cleared, and compatible with study designs that require pulse-resolved sampling. The longer-acting analogs (CJC-1295 with DAC, tesamorelin) are appropriate when sustained receptor engagement is the research question.
Preclinical characterisation
Preclinical work on sermorelin has characterised GH-secretion endpoints in rodent and non-human primate models, both as a stand-alone stimulus and in combination with GHRPs (GHRP-2, GHRP-6, ipamorelin, hexarelin). The GHRH-plus-GHRP synergy first characterised with sermorelin remains the mechanistic reference for later combinations involving longer-acting GHRH analogs.
Diagnostic-testing applications have used sermorelin as a probe of pituitary responsiveness, distinguishing hypothalamic GHRH deficiency from primary somatotroph failure. This diagnostic framing is another lens on why the short half-life is useful — a probe that clears quickly is appropriate for provocative testing.
Comparative context: sermorelin, CJC-1295, tesamorelin
Within the GHRH-analog family, three compounds define the practical landscape: sermorelin as the short-acting reference, CJC-1295 as the long-acting fatty-acid or maleimidopropionic-acid modified analog, and tesamorelin as an intermediate-half-life analog with different substitutions.
Tesamorelin carries an N-terminal trans-3-hexenoyl group and additional stabilising substitutions, producing a molecule with a plasma half-life longer than sermorelin but shorter than CJC-1295-DAC. Comparing all three illustrates how modifications to the same 29-residue core sequence change pharmacokinetics — the same peptide backbone tuned across a wide half-life range.
Analytical characterisation
Sermorelin is characterised by reversed-phase HPLC for purity and mass spectrometry for identity. The theoretical monoisotopic mass of the amide form is approximately 3358 Da. Chromatographic methods should be tuned to resolve related deletion sequences and any oxidation impurities at methionine residues.
Because sermorelin is a 29-residue linear peptide with no unusual chemistries, standard peptide-characterisation methods are directly applicable. A batch COA should include HPLC purity, mass-spec identity, and — where relevant — assessment of related peptide impurities.
Reconstitution and storage
Lyophilised sermorelin is soluble in aqueous buffer and reconstituted with bacteriostatic or sterile water. As a linear peptide without disulfide bridges or unusual chemistries, its stability profile is broadly consistent with other similarly-sized research peptides.
Store lyophilised material sealed and cold; aliquot reconstituted material into single-use portions. Working-concentration stability in solution should be characterised for the specific buffer system used in a given study.
Worked examples
Reconstituting a 5 mg sermorelin vial
- 01Bring the sealed vial to room temperature before opening.
- 02Wipe the stopper with an alcohol swab.
- 03Add 2.5 mL of bacteriostatic water for a nominal 2 mg/mL working concentration.
- 04Let the diluent run down the inside wall of the vial. Do not spray onto the solid.
- 05Swirl gently until dissolved.
- 06Label with lot, concentration, diluent, and reconstitution date.
Storage protocol
- 01Lyophilised material: sealed and desiccated at 2–8 °C short-term or −20 °C long-term.
- 02Reconstituted material: refrigerated at 2–8 °C, aliquotted into single-use portions.
- 03Track freeze-thaw cycles per aliquot.
- 04For provocative-testing designs, prepare working solutions fresh where practical given sermorelin's short in-vivo half-life.
Frequently asked questions
What is the difference between sermorelin and CJC-1295?
Sermorelin is native GHRH(1-29) with no protease-stabilising modifications. CJC-1295 is the same 29-residue backbone with substitutions blocking DPP-4 cleavage and, in the DAC form, a linker for covalent albumin binding. Sermorelin is short-acting; CJC-1295 (particularly the DAC form) is long-acting.
Why is sermorelin useful in research if it is short-acting?
The short half-life closely resembles endogenous GHRH pulsatility and is well-suited to provocative testing of pituitary responsiveness and to study designs that need to preserve pulse-resolved GH secretion. Long-acting analogs are appropriate for different research questions.
What receptor does sermorelin engage?
The GHRH receptor — a class B G-protein-coupled receptor on somatotroph cells of the anterior pituitary, coupling primarily to Gαs and cAMP. GHRH receptor engagement stimulates GH release.
What analytical tests confirm identity and purity?
Reversed-phase HPLC quantifies purity; mass spectrometry confirms identity against the expected molecular weight near 3358 Da for the amide form. A batch COA should include both.
How should reconstituted sermorelin be stored?
Refrigerated at 2–8 °C, aliquotted into single-use portions to minimise freeze-thaw exposure.
References
Selected published research referenced in this article.
- 01Guillemin R, Brazeau P, Bohlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585–587. PubMed
- 02Rivier J, Spiess J, Thorner M, Vale W. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature. 1982;300(5889):276–278. PubMed
- 03Ling N, Esch F, Bohlen P, Brazeau P, Wehrenberg WB, Guillemin R. Isolation, primary structure, and synthesis of human hypothalamic somatocrinin: growth hormone-releasing factor. Proc Natl Acad Sci U S A. 1984;81(14):4302–4306. PubMed
- 04Kubiak TM, Kelly CR, Krabill LF. In vitro metabolic degradation of a bovine growth hormone-releasing factor analog Leu27-bGRF(1-29)NH2 in bovine and porcine plasma. Correlation with plasma dipeptidylpeptidase activity. Drug Metab Dispos. 1989;17(4):393–397. PubMed
- 05Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006;1(4):307–308. PubMed
- 06Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805. PubMed